½ÃÀ庸°í¼­
»óǰÄÚµå
1618170

¾ç¸· ½ÃÀå ±âȸ, ¼ºÀå ÃËÁø¿äÀÎ, »ê¾÷ µ¿Ç⠺м® ¹× ¿¹Ãø(2024-2032³â)

Amniotic Membrane Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 - 2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Global Market Insights Inc. | ÆäÀÌÁö Á¤º¸: ¿µ¹® 130 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°è ¾ç¸· ½ÃÀåÀº 2023³â 17¾ï ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2024-2032³â°£ ¿¬Æò±Õ 7.9%ÀÇ ¼ºÀå·üÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¾ç¸·Àº ¼¶¼¼Çϰí À¯¿¬ÇÑ Á¶Á÷À¸·Î ÀӽŠ±â°£ µ¿¾È ¾ç¸·³¶¿¡ µÑ·¯½Î¿© Áß¿äÇÑ ¿µ¾ç¼Ò¿Í ¼ºÀå ÀÎÀÚ¸¦ °ø±ÞÇϸ鼭 žƸ¦ º¸È£ÇÏ´Â º¸È£¸· ¿ªÇÒÀ» ÇÕ´Ï´Ù. Ãâ»ê ÈÄ ÀÌ ¸·Àº Ä¡À¯¸¦ ÃËÁøÇÏ´Â Àç»ý Ư¼ºÀ¸·Î ÀÎÇØ ´Ù¾çÇÑ Ä¡·á¿Í ¼ö¼ú¿¡ À¯¿ëÇÏ°Ô ¾²ÀδÙ. Àç»ýÀÇ·á¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö´Â °ÍÀº Áß¿äÇÑ ¼ºÀå ÃËÁøÁ¦°¡ µÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ ºÎ¹®Àº Áٱ⼼Æ÷ Ä¡·á, Á¶Á÷°øÇÐ, »ýüÀç·á¿Í °°Àº Çõ½ÅÀûÀÎ ¹æ¹ýÀ» ÅëÇØ ¼Õ»óµÈ Á¶Á÷°ú Àå±â¸¦ º¹±¸Çϰųª ´ëüÇÏ´Â °ÍÀ» ¸ñÇ¥·Î ÇÕ´Ï´Ù.

¾ç¸·Àº ÁÖ·Î ¾ç¸·ÀÇ Æ¯Â¡ÀûÀΠƯ¼ºÀ¸·Î ÀÎÇØ ÀÌ·¯ÇÑ ÀÀ¿ë ºÐ¾ß¿¡¼­ ÀáÀç·ÂÀ» ÀÎÁ¤¹Þ°í ÀÖ½À´Ï´Ù. ÃÖ±Ù ¿¬±¸¿¡ µû¸£¸é ¾ç¸·¿¡ ÁÖ¿ä »ý¸®È°¼º ºÐÀÚ°¡ Á¸ÀçÇÑ´Ù´Â »ç½ÇÀÌ ¹àÇôÁ® Àç»ýÀÇÇп¡¼­ ¾ç¸·ÀÇ ¿ªÇÒÀÌ °­È­µÇ°í ÀÖ½À´Ï´Ù. Á¦Ç° À¯Çüº°·Î ½ÃÀåÀº ³Ãµ¿ º¸Á¸ ¾ç¸·°ú µ¿°á °ÇÁ¶ ¾ç¸·À¸·Î ºÐ·ùµË´Ï´Ù. ³Ãµ¿ º¸Á¸ ºÎ¹®Àº ÁÖ·Î ¿©·¯ ÀÇ·á ºÎ¹®¿¡ °ÉÃÄ ±¤¹üÀ§ÇÏ°Ô Àû¿ëµÇ¾î 2032³â±îÁö 17¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¾È°ú¿¡¼­ ³Ãµ¿ º¸Á¸µÈ ¾ç¸·Àº Áö¼ÓÀûÀÎ »óÇÇ °á¼Õ, ±Ë¾ç, È­ÇÐÀû È­»óÀ» Æ÷ÇÔÇÑ ´Ù¾çÇÑ °¢¸· °á¼ÕÀ» Ä¡·áÇÏ´Â µ¥ »ç¿ëµË´Ï´Ù. ÀÌ ¿ëµµ´Â ¿°Áõ°ú ÈäÅ͸¦ ÃÖ¼ÒÈ­Çϸ鼭 Ä¡À¯¸¦ ÃËÁøÇÏ´Â µ¥ µµ¿òÀÌ µÇ¸ç, 2023³â ¾È°ú ºÎ¹®Àº 3¾ï 4,210¸¸ ´Þ·¯ÀÇ ¸ÅÃâÀ» ±â·ÏÇÏ¸ç ½ÃÀåÀ» ÁÖµµÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¾ç¸· À̽Ä(AMT)Àº ÀÌ ºÎ¹®¿¡¼­ ¿©·¯ ¾È±¸ Ç¥¸é Àå¾Ö¸¦ °ü¸®Çϱâ À§ÇØ È°¿ëµÇ°í ÀÖ½À´Ï´Ù.

½ÃÀå ¹üÀ§
½ÃÀÛ ¿¬µµ 2023³â
¿¹Ãø ¿¬µµ 2024-2032³â
½ÃÀÛ °¡°Ý 17¾ï ´Þ·¯
¿¹»ó °¡°Ý 32¾ï ´Þ·¯
CAGR 7.9%

¾ç¸·Àº ŹÝÀÇ °¡Àå ¾ÈÂÊ ÃþÀ¸·Î, Äݶó°Õ ¼ººÐÀ» ÅëÇØ »óÇǼ¼Æ÷ÀÇ ¼ºÀåÀ» µ½°í, ¿°ÁõÀ» ¾ïÁ¦Çϰí, Ç÷°ü ½Å»ýÀ» ¹æÁöÇϸç, ¹Î°¨ÇÑ ½Å°æ ¸»´ÜÀ» µ¤¾î ÁøÅë È¿°ú¸¦ °¡Á®¿À´Â µî ´Ù¾çÇÑ ÀÌÁ¡À» °¡Áö°í ÀÖ½À´Ï´Ù. ¹Ì±¹¿¡¼­´Â ¾ç¸· ½ÃÀåÀÌ 2032³â±îÁö 11¾ï ´Þ·¯ ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¼ºÀåÀº ÷´Ü ÀÇ·á ½Ã¼³°ú ÁÖ¿ä »ê¾÷ ÁøÃâ±â¾÷µé¿¡ ±âÀÎÇÕ´Ï´Ù. ±Þ¼ÓÇÑ ±â¼ú ¹ßÀü°ú ÇÔ²² Àç»ýÀÇ·á¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁü¿¡ µû¶ó ½ÃÀå È®´ë°¡ ´õ¿í °¡¼ÓÈ­µÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú Á¶»ç ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå »ê¾÷ ÀλçÀÌÆ®

  • »ýÅÂ°è ºÐ¼®
  • »ê¾÷¿¡ ´ëÇÑ ¿µÇâ¿äÀÎ
    • ¼ºÀå ÃËÁø¿äÀÎ
      • Àç»ýÀÇ·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡
      • ¸¸¼º â»ó Áõ°¡
      • ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö¿Í Á¶Á÷°øÇÐ Áøº¸
      • ¾ç¸· Á¦Ç°¿¡ ´ëÇÑ Àνİú ¼ö¿ë Áõ°¡
    • »ê¾÷ÀÇ ÀáÀçÀû ¸®½ºÅ©¿Í °úÁ¦
      • ¾ç¸· Á¦Ç° º¸Á¸ ±â°£ Á¦ÇÑ
      • ¾ö°ÝÇÑ ±ÔÁ¦ ½ÃÃ¥
  • ¼ºÀå °¡´É¼º ºÐ¼®
  • ±ÔÁ¦ »óȲ
  • »óȯ ½Ã³ª¸®¿À
  • ±â¼ú »óȲ
  • Porter's Five Forces ºÐ¼®
  • PESTEL ºÐ¼®

Á¦4Àå °æÀï ±¸µµ

  • ¼­·Ð
  • ±â¾÷ Á¡À¯À² ºÐ¼®
  • ±â¾÷ ¸ÅÆ®¸¯½º ºÐ¼®
  • ÁÖ¿ä ½ÃÀå ÁøÃâ±â¾÷ °æÀï ºÐ¼®
  • °æÀï Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º
  • Àü·« ´ë½Ãº¸µå

Á¦5Àå ½ÃÀå ÃßÁ¤¡¤¿¹Ãø : Á¦Ç°º°, 2018-2032³â

  • ÁÖ¿ä µ¿Çâ
  • µ¿°áº¸Á¸
  • µ¿°á°ÇÁ¶

Á¦6Àå ½ÃÀå ÃßÁ¤¡¤¿¹Ãø : ¿ëµµº°, 2018-2032³â

  • ÁÖ¿ä µ¿Çâ
  • ¼ö¼úâ
  • ¾È°ú
  • Áٱ⼼Æ÷ »ý¹°ÇÐ
  • Àç»ýÀÇ·á
  • »êÀü Áø´Ü
  • Á¤Çü¿Ü°ú
  • ÇǺΰúÇÐ
  • ¼ºÇü ¿Ü°ú
  • Ä¡°ú
  • ºÎÀΰú

Á¦7Àå ½ÃÀå ÃßÁ¤¡¤¿¹Ãø : ÃÖÁ¾ ¿ëµµº°, 2018-2032³â

  • ÁÖ¿ä µ¿Çâ
  • º´¿ø
  • ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC)
  • Àü¹® Ŭ¸®´Ð
  • ¿¬±¸ ¹× Çмú±â°ü
  • ±âŸ

Á¦8Àå ½ÃÀå ÃßÁ¤¡¤¿¹Ãø : Áö¿ªº°, 2018-2032³â

  • ÁÖ¿ä µ¿Çâ
  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • µ¶ÀÏ
    • ¿µ±¹
    • ÇÁ¶û½º
    • ½ºÆäÀÎ
    • ÀÌÅ»¸®¾Æ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • ÀϺ»
    • Àεµ
    • È£ÁÖ
    • Çѱ¹
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ¾Æ¸£ÇîÆ¼³ª
    • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦9Àå ±â¾÷ °³¿ä

  • Amnio Technology, LLC
  • Applied Biologics LLC
  • BioTissue Holdings Inc.
  • Celularity Inc.
  • Corza Health, Inc.
  • Integra LifeSciences Holdings Corporation
  • MiMedx Group, Inc.
  • Organogenesis Holdings Inc.
  • Skye Biologics, Inc.
  • Smith & Nephew plc
LSH 25.01.09

The Global Amniotic Membrane Market was valued at USD 1.7 billion in 2023 and is projected to experience a CAGR of 7.9% from 2024 to 2032. The amniotic membrane is a delicate, flexible tissue that lines the amniotic sac during pregnancy, serving as a protective barrier for the developing fetus while supplying vital nutrients and growth factors. Following childbirth, this membrane finds utility in various medical treatments and surgeries due to its regenerative properties that promote healing. The increasing focus on regenerative medicine is expected to be a significant growth driver. This field aims to restore or replace damaged tissues and organs through innovative methods such as stem cell therapy, tissue engineering, and biomaterials.

Amniotic membranes are gaining recognition for their potential in these applications, primarily because of their distinctive properties. Recent studies have highlighted the presence of key bioactive molecules within the amniotic membrane, reinforcing its role in regenerative medicine. In terms of product types, the market can be categorized into cryopreserved and lyophilized amniotic membranes. The cryopreserved segment is anticipated to reach USD 1.7 billion by 2032, primarily due to its extensive application across multiple medical disciplines.

In ophthalmology, cryopreserved amniotic membranes are used to treat various corneal defects, including persistent epithelial defects, ulcers, and chemical burns. This application aids in accelerating healing while minimizing inflammation and scarring. The ophthalmology segment led the market in 2023, with revenues reaching USD 342.1 million. Amniotic membrane transplantation (AMT) is utilized in this field to manage several ocular surface disorders.

Market Scope
Start Year2023
Forecast Year2024-2032
Start Value$1.7 Billion
Forecast Value$3.2 Billion
CAGR7.9%

The amniotic membrane, being the innermost layer of the placenta, provides various benefits, such as supporting epithelial cell growth through its collagen composition, reducing inflammation, preventing angiogenesis, and offering analgesic effects by covering sensitive nerve endings. In the United States, the amniotic membrane market is projected to reach USD 1.1 billion by 2032. This growth can be attributed to advanced healthcare facilities and key industry players. The rising emphasis on regenerative medicine, in line with rapid technological advancements, is expected to fuel further market expansion.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market segmentation
  • 1.2 Market definition
  • 1.3 Research design
  • 1.4 Market size estimates and calculations
  • 1.5 Key trends for market estimates
  • 1.6 Forecast model
  • 1.7 Primary research & validation
    • 1.7.1 Primary sources
    • 1.7.2 Data mining sources
      • 1.7.2.1 Paid sources
      • 1.7.2.2 Public sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis, 2018 - 2032
  • 2.2 Product trends
  • 2.3 Application trends
  • 2.4 End-use trends
  • 2.5 Regional trends

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Growing demand for regenerative medicine
      • 3.2.1.2 Rising incidence of chronic wounds
      • 3.2.1.3 Advancements in biotechnology and tissue engineering
      • 3.2.1.4 Increasing awareness and acceptance of amniotic membrane products
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 Limited shelf life of amniotic membrane products
      • 3.2.2.2 Stringent regulatory polices
  • 3.3 Growth potential analysis
    • 3.3.1 By product
    • 3.3.2 By application
    • 3.3.3 By end-use
  • 3.4 Regulatory landscape
  • 3.5 Reimbursement scenario
  • 3.6 Technology landscape
  • 3.7 Porter's analysis
  • 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company market share analysis
  • 4.3 Company matrix analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2018 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Cryopreserved
  • 5.3 Lyophilized

Chapter 6 Market Estimates and Forecast, By Application, 2018 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Surgical wounds
  • 6.3 Ophthalmology
  • 6.4 Stem cell biology
  • 6.5 Regenerative medicine
  • 6.6 Prenatal diagnosis
  • 6.7 Orthopedics
  • 6.8 Dermatology
  • 6.9 Plastic surgery
  • 6.10 Dentistry
  • 6.11 Gynecology

Chapter 7 Market Estimates and Forecast, By End Use, 2018 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Hospitals
  • 7.3 Ambulatory surgical centers (ASCs)
  • 7.4 Specialty clinics
  • 7.5 Research and academic institutes
  • 7.6 Other end-users

Chapter 8 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 France
    • 8.3.4 Spain
    • 8.3.5 Italy
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 South Korea
    • 8.4.6 Rest of Asia Pacific
  • 8.5 Latin America
    • 8.5.1 Brazil
    • 8.5.2 Mexico
    • 8.5.3 Argentina
    • 8.5.4 Rest of Latin America
  • 8.6 Middle East and Africa
    • 8.6.1 South Africa
    • 8.6.2 Saudi Arabia
    • 8.6.3 UAE
    • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

  • 9.1 Amnio Technology, LLC
  • 9.2 Applied Biologics LLC
  • 9.3 BioTissue Holdings Inc.
  • 9.4 Celularity Inc.
  • 9.5 Corza Health, Inc.
  • 9.6 Integra LifeSciences Holdings Corporation
  • 9.7 MiMedx Group, Inc.
  • 9.8 Organogenesis Holdings Inc.
  • 9.9 Skye Biologics, Inc.
  • 9.10 Smith & Nephew plc
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦